Human papillomavirus (HPV) is responsible for nearly 70% of head and neck cancers in the United States, making it the most common cancer caused by the virus. Alarmingly, these rates continue to rise each year. Unlike HPV-related cervical cancer, there is no screening test for HPV-associated head and neck cancers. As a result, most patients receive a diagnosis only after the tumor has grown significantly, causing symptoms and spreading to lymph nodes.
Early screening could transform outcomes by allowing timely treatment interventions and reducing the intensity of therapy required.
Breakthrough with HPV-DeepSeek
In a study published in the Journal of the National Cancer Institute, researchers from Mass General Brigham report that a novel liquid biopsy tool, HPV-DeepSeek, can detect HPV-associated head and neck cancer up to 10 years before symptoms appear.
Lead study author Daniel L. Faden, MD, FACS, head and neck surgical oncologist and principal investigator at the Mike Toth Head and Neck Cancer Research Center, explained,
“Our study shows for the first time that we can accurately detect HPV-associated cancers in asymptomatic individuals many years before they are ever diagnosed. By catching cancers earlier, we can improve treatment success and reduce the long-term side effects of therapy.”
How the Test Works
HPV-DeepSeek uses whole-genome sequencing to find microscopic fragments of HPV DNA shed by tumors into the bloodstream. Previous studies from this team showed the test achieved 99% specificity and 99% sensitivity at the first clinical presentation—far outperforming existing diagnostic methods.
Study Design and Key Findings
Researchers analysed 56 blood samples from the Mass General Brigham Biobank, including 28 samples from individuals who later developed HPV-associated head and neck cancer and 28 from healthy controls.
- HPV-DeepSeek detected tumor DNA in 22 out of 28 pre-diagnosis cancer samples.
- All 28 control samples tested negative, demonstrating the test’s high specificity.
- The earliest positive detection occurred 7.8 years before diagnosis, with accuracy improving in samples collected closer to diagnosis.
When researchers applied machine learning, they enhanced the test’s performance, correctly identifying 27 out of 28 cancer cases, even up to 10 years before diagnosis.
Next Steps
As reported by medicalxpress, the team is now validating these results in a larger, blinded study using hundreds of samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial at the National Cancer Institute.
Promise for the Future
If confirmed, HPV-DeepSeek could enable routine screening for HPV-associated head and neck cancers, allowing detection at the earliest stages. This breakthrough could dramatically improve patient outcomes and quality of life by reducing the need for aggressive, side-effect-heavy treatments.